Hope Care raises €6M Series A to take regulated remote patient monitoring across Europe

Hope Care (Portugal) has closed a €6 million Series A led by Iberis Capital, with participation from Vieira de Matos – VDM Capital S.A. and existing investor Buenavista Equity Partners. Founded in 2012 by José Paulo Carvalho, Hope Care has spent fourteen years building its OpMA platform — a regulated remote patient monitoring system for chronic disease — before raising this round. The capital goes toward European expansion, commercial scaling, and accelerated deployments across healthcare institutions and insurance companies.

The OpMA platform integrates three data streams that healthcare monitoring systems typically treat in isolation: data from medical devices (blood glucose monitors, blood pressure cuffs, oximeters, cardiac monitors), patient-reported outcomes (symptoms, adherence, wellbeing surveys), and clinical workflow data (consultation notes, care plan milestones, alert thresholds). The result is a unified view of a patient's status that can trigger alerts for clinical teams and generate documentation for payers — combining functions that typically require separate systems and manual handoffs.

What a decade of deployment looks like

Hope Care's fourteen-year operational history distinguishes it from most Series A companies in the digital health space. Most digital health startups of this vintage are either dead, acquired, or have raised growth capital several times over by this point. That Hope Care reaches Series A in 2026 after a 2012 founding is unusual and worth examining directly.

The most plausible explanation is the nature of healthcare procurement: contracts with hospitals and insurers are typically long-cycle, low-churn, and institutionally conservative — a profile that rewards patient companies with genuine clinical relationships but does not reward growth-at-all-costs capital deployment. A platform that has been live in real hospital and insurance environments for over a decade carries clinical validation that a two-year-old startup cannot manufacture. That validation is what Iberis Capital is backing.

José Paulo Carvalho, CEO, described the logic plainly: "After more than a decade working with healthcare institutions, we have built a regulated platform that delivers measurable outcomes for patients, healthcare professionals and healthcare systems."

The regulated framing is not incidental. Remote patient monitoring platforms in Europe must navigate a patchwork of national medical device regulations, data protection requirements, and reimbursement frameworks. A platform that is already operating inside those frameworks in Portugal has cleared the baseline compliance hurdles that newcomers spend years negotiating.

The European play

The fund will be deployed across three vectors: expanding the commercial team to address European healthcare markets, scaling operational capacity to manage deployments at greater volume, and deepening integrations with the medical device ecosystem to broaden the range of chronic conditions the platform can support.

Iberis Capital, a Portugal-focused but pan-European early-stage VC, brings specific knowledge of the Iberian healthcare market and relationships with institutional buyers in both Portugal and Spain — a natural first step in the regional expansion. The presence of Buenavista Equity Partners as an existing re-participant signals that investors who have been alongside the company throughout its slow build have not grown impatient with its pace.

The honest question is whether Hope Care's deliberate, institution-first approach to growth will survive contact with the faster procurement timelines that venture-backed scaling requires. The company now has €6 million to answer it.